← All news

GLP-1 Drugs may risk investments in other essential treatments

Microscope section of a fresh blood clot with pink fibrin layers and red blood cells, illustrating the FDA approval of Bayer's factor XIa inhibitor asundexian for stroke prevention

By Bahram Hassanpourfard, Epidemiologist

Weekly briefing · 8 to 14 November 2026

Public health and prevention

Diabetes care in poorer settings drew attention from two directions. The WHO published its first guideline on diagnosing and managing type 1 diabetes in children and adolescents up to 19, written to address global inequalities in outcomes and access and focused on primary and secondary care in resource-limited settings. The Access to Medicine Foundation warned that the industry’s focus on lucrative GLP-1 weight-loss medicines risks diverting attention and investment from essential treatments such as insulin.

Cambridge research estimated that meeting WHO air quality guidelines could save more than nine million lives a year in low- and middle-income countries. In screening, the American Cancer Society moved to risk-based PSA testing starting at 45 or 50, with updated follow-up thresholds. Scotland held its first Alcohol Action Day, centred on gaps in support for those affected, and Guyana moved to restrict imports of vaping products, except those approved by health authorities. For antimicrobial resistance specialists, experts debated whether cefiderocol should rank alongside aztreonam-avibactam against NDM-producing Enterobacterales.

Healthcare providers

General practice in England heads into winter under financial pressure. The BMA warned that the plan unveiled by the prime minister, Andy Burnham, to reallocate £40m from GP budgets so practices can proactively identify and support vulnerable patients will further strain struggling practices. NHS England published changes to the 2026/27 Network Contract DES covering proactive care for patients at greatest risk of avoidable hospital admission. In Northern Ireland, the Department of Health announced an agreed GP contract with additional investment.

In hospitals, the Royal College of Emergency Medicine said more than 170,000 people waited over 12 hours in emergency departments in October and called for immediate action before a brutal winter. GIRFT issued a shared framework for people with mental health needs in urgent and emergency care, setting national waiting time expectations, escalation triggers and accountability. A global Microsoft outage on 13 November disrupted NHS services, which fell back on other IT systems or paper records to keep critical services and appointments running. An IT outage also forced an extension to the mandatory community pharmacy workforce survey.

Research and trials

Incretin-based drugs kept moving beyond weight loss. The glucagon/GLP-1 dual agonist pemvidutide reduced heavy drinking days per week in moderate-to-severe alcohol use disorder in the phase II RECLAIM study, while survodutide, from the same class, met its cardiovascular safety endpoint in people with obesity and established cardiovascular disease, chronic kidney disease or raised cardiovascular risk. Lilly’s oral GLP-1 Foundayo reduced sleep apnoea severity in phase 3 data presented at AHA and Lilly is approaching the FDA for a label expansion, although it appears less effective than injectable Zepbound.

In gene editing, Beam Therapeutics reported that its base-edited cell therapy risto-cel reduced the most painful complications of sickle cell disease for a full year in a phase 1/2 study, ahead of a potential FDA filing by year-end that would set it against Casgevy and Lyfgenia. Nature reported that a CRISPR therapy editing genes inside the body is poised for its first FDA approval. In oncology, a PROTEUS substudy at ESMO found that adding apalutamide and androgen deprivation before and after radical prostatectomy beat surgery alone in high-risk prostate cancer. In the EMPIRICAL trial, empirical tuberculosis treatment did not reduce deaths in African infants with HIV and severe pneumonia.

Deals and markets

Obesity remains the magnet for capital. Blackstone Life Sciences agreed to pay up to $1.5bn of development costs through 2028 for berobenatide, the monthly GLP-1 shot Pfizer gained by buying Metsera for up to $10bn last year. Earlier in the month, Lilly agreed that Hims & Hers can offer Zepbound and Foundayo through its telehealth platform. Argenx agreed to buy Unnatural Products for $550m upfront and up to $595m in milestones, adding an oral macrocyclic peptide platform to an immunology pipeline built on antibodies. Wearable maker Oura is paying $625m in cash for AI primary care start-up Counsel Health.

For the outsourcing supply chain, the Pentagon removed WuXi AppTec from its list of Chinese military companies, though redesignation remains possible. Capital markets were mixed: Sanofi-backed Windward Bio raised $175m in its Nasdaq IPO plus $50m from Sanofi to develop respiratory drugs licensed from China, while Rezera delayed its listing citing market conditions. Milestone Pharmaceuticals cut headquarters staff and about 30% of operating costs after its arrhythmia drug Cardamyst made $1m in third-quarter sales.

Approvals and safety

The FDA approved Bayer’s Sunharbo (asundexian), the first factor XIa inhibitor, for use with antiplatelet therapy to reduce stroke risk after a recent mild-to-moderate non-cardioembolic ischaemic stroke or high-risk transient ischaemic attack, opening a class designed to prevent clots without raising bleeding risk. Another US first followed, with Gazyva approved as the first drug for primary membranous nephropathy. The agency also approved Imfinzi with Padcev before cystectomy, then Imfinzi alone after surgery, for muscle-invasive bladder cancer in patients who cannot have cisplatin, and Merck KGaA’s pimicotinib, licensed from Abbisko, for tenosynovial giant cell tumour. In Europe, the CHMP recommended seven new medicines, including AstraZeneca’s baxdrostat for hypertension and aumolertinib for non-small cell lung cancer, and confirmed on re-examination its refusal of KemSu, a sufentanil and ketamine product for acute pain in children.

The MHRA approved retifanlimab for anal canal squamous cell carcinoma and awarded Innovation Passports to candidates in lung cancer, Huntington’s disease and Alzheimer’s disease. On safety, a cohort study linked early-pregnancy doxycycline exposure to a higher risk of pregnancy loss than other antibiotics, Medline updated its recall of beds, rails and mattresses over fire and entrapment risks, and a lot of vancomycin injection was recalled for particulate matter.


Source: Life Sciences Hub, lifesciences.apotekanalytics.com